Practical Model-based Approaches for Phase 1 Oncology Trials
Innovations in statistics, programming and data management are changing the very nature of clinical development. Cytel thought-leaders reveal cutting-edge techniques that streamline and truly accelerate product developmental at the clinical trial, program and portfolio level. Featuring, Simulation and biomarkers speeding development at Merck, Adaptive trial design methodology and software demonstrations, Leading independent authorities and Cytel speakers at User Group Meetings. www.cytel.com +1 .617.661.2011
▶︎
Synthetic Controls In Clinical Trials
▶︎
Adaptive Trial Designs - Introduction for Non-Statisticians
▶︎
Protocol Design & Development: What You Need to Know to Ensure a Successful Study
▶︎
BOIN design for non-statisticians
▶︎
Ready to Adopt the Regulatory CDISC Standards for Next Clinical Trial?
▶︎
Biostatistics for Non-Statisticians: Understanding Different Types of Analyses and When to Use Each
▶︎
June 2025 MicroMasters Program Joint Completion Celebration for SCM, DEDP, PoM, SDS, and Fin
▶︎
Deep Insight Into Immuno-Oncology: Immunotherapy Pathways, Targets, and Biomarkers
▶︎
Supply chain simulation, AI and digital twins: theory to use cases and implementation blueprints
▶︎
How Proctor’s texts in Karen Read lawsuit could free dangerous criminals
▶︎
Webinar: Phase I trials in oncology: Pros and cons of current designs
▶︎
AI in Education: Navigating Teaching and Assessing Student Learning in the GenAI Era
▶︎
Do we need Phase 3 trials in oncology?
▶︎
Bayesian Optimal Interval Design Fundamentals
▶︎
Head-to-Head Comparisons using Real-World Data
▶︎
The First 90 Days, ft. Michael Watkins and Asha Aravindakshan, SF ’17
▶︎
Clinical Research Statistics for Non-Statisticians
▶︎
MERIT Webinar: Lugano and Oncology Imaging Endpoints
▶︎
Assessing activity in early-phase trial in oncology: current designs for expansion cohorts & phase 2
▶︎